Table 1 ACE2 expression associated with patient demographics of normal control and cancer cohorts.

From: Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes

Characteristic

ACE2 Expression (TPM)

Cancer

Normal

N samples

Mean

Median

Range

p-value

N samples

Mean

Median

Range

p-value

Gender

Female

22493

4.8

0.74491

0.006422–3385.94

 < 0.0001

75

3.53

0.73799

0–102.946

0.02

Male

16135

6

0.88101

0.007438–883.672

52

22

1.58763

0–409.937

Age Group (years)

< 65

19944

5.8

0.804511

0.006422–3385.94

< 0.0001

70

8.62

1.23194

0–202.582

0.24

≥ 65

18684

4.76

0.790774

0.007306–1495.36

57

14.1

0.94495

0–409.937

Smoking status

Current smoker

1039

3.49

0.784241

0.008451–204.511

0.42

3

6.5

0.56718

0.125167–18.794

0.79

Lifelong non-smoker

322

3.38

0.990115

0.008251–105.225

0

NA

NA

NA

Light smoker (<15 packs/yr)

2479

4.13

0.900375

0.008565–549.111

6

69.1

1.00519

0.091297–409.937

Not reported

34788

5.45

0.786538

0.006422–3385.94

118

8.25

1.02695

0–208.806

  1. P-values were calculated using the Kruskal–Wallis rank sum test for numeric variables and Pearson’s Chi-squared test for categorical variables.
Back to article page